AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2026
Feb 6, 2026
31920_dirs_2026-02-06_d0c7c85a-3879-4d1c-84ad-ef270bbf6b74.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2026-02-04
Reporting Person: McCamish Mark Anthony (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-04 | Ordinary Shares | G | 67025 | — | Disposed | 0 | Indirect |
| 2026-02-04 | Ordinary Shares | G | 67025 | — | Acquired | 67025 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 22000 | Direct |
Footnotes
F1: On February 4, 2026, the Reporting Person transferred 67,025 shares from Matthew 5 LLC to the McCamish Charitable Remainder Trust.
F2: Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.
F3: Shares held by McCamish Charitable Remainder Trust, of which the Reporting Person and his spouse are income beneficiaries. The Reporting Person disclaims beneficial ownership except to the extent of his and his spouse's pecuniary interest therein.